[{"orgOrder":0,"company":"Fenix Innovation Group","sponsor":"Neurotech International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NTI164","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Fenix Innovation Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fenix Innovation Group \/ Neurotech International","highestDevelopmentStatusID":"7","companyTruncated":"Fenix Innovation Group \/ Neurotech International"},{"orgOrder":0,"company":"Proniras","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tezampanel","moa":"Glutamate receptor ionotropic AMPA | Glutamate receptor ionotropic kainate","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Proniras \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"ELE-101","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"7","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Laboratorium Ofichem B.V","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Laboratorium Ofichem B.V"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Proniras","sponsor":"Indiana University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tezampanel","moa":"Glutamate receptor ionotropic AMPA | Glutamate receptor ionotropic kainate","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Proniras \/ Indiana University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/ Indiana University School of Medicine"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10380","moa":"Unknown","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"UT Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ UT Health San Antonio","highestDevelopmentStatusID":"7","companyTruncated":"PharmAla Biotech \/ UT Health San Antonio"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Bruyere Research Institute | The Ottawa Hospital | St. Joseph's Healthcare Hamilton | CHU de Quebec-Universite Laval | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Jewish General Hospital | William Osler Health System | Queen's ","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ottawa Hospital Research Institute \/ Bruyere Research Institute | The Ottawa Hospital | St. Joseph's Healthcare Hamilton | CHU de Quebec-Universite Laval | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Jewish General Hospital | William Osler Health System | Queen's ","highestDevelopmentStatusID":"7","companyTruncated":"Ottawa Hospital Research Institute \/ Bruyere Research Institute | The Ottawa Hospital | St. Joseph's Healthcare Hamilton | CHU de Quebec-Universite Laval | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Jewish General Hospital | William Osler Health System | Queen's "},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Zhejiang Jingxin Pharmaceutical","sponsor":"Shanghai Mental Health Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JX11502MA","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang Jingxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zhejiang Jingxin Pharmaceutical \/ Shanghai Mental Health Center","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang Jingxin Pharmaceutical \/ Shanghai Mental Health Center"},{"orgOrder":0,"company":"DemeRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibogaine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10380","moa":"Unknown","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Jingxin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JX11502MA","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang Jingxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zhejiang Jingxin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang Jingxin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"DemeRx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Ibogaine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ ATAI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ IMP Clinical Supply Services"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"CSIRO","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ CSIRO","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ CSIRO"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Granite Point Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Delpor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ Inapplicable"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Phytanix Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagenic Therapeutics \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Protagenic Therapeutics \/ Phytanix Bio"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Phytanix Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagenic Therapeutics \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Protagenic Therapeutics \/ Phytanix Bio"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"New York State Psychiatric Institute \/ BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI","highestDevelopmentStatusID":"7","companyTruncated":"New York State Psychiatric Institute \/ BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"CMND-100","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine Inc. \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine Inc. \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Consumer Wellness Solutions","sponsor":"Vincere Health | Maryland State Tobacco Quitline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Consumer Wellness Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Consumer Wellness Solutions \/ Vincere Health | Maryland State Tobacco Quitline","highestDevelopmentStatusID":"7","companyTruncated":"Consumer Wellness Solutions \/ Vincere Health | Maryland State Tobacco Quitline"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institute of Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ National Institute of Mental Health","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ National Institute of Mental Health"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"MAC Clinical Research | ERT: Clinical Trial Technology Solutions | Hammersmith Medicines Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DMX-1002","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ MAC Clinical Research | ERT: Clinical Trial Technology Solutions | Hammersmith Medicines Research","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life Sciences \/ MAC Clinical Research | ERT: Clinical Trial Technology Solutions | Hammersmith Medicines Research"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Seaport Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Seaport Therapeutics \/ General Atlantic"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Foundation for a Smoke Free World | Rose Research Center | Segal Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ Foundation for a Smoke Free World | Rose Research Center | Segal Trials","highestDevelopmentStatusID":"7","companyTruncated":"Embera NeuroTherapeutics \/ Foundation for a Smoke Free World | Rose Research Center | Segal Trials"},{"orgOrder":0,"company":"BioIntegrate","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioIntegrate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioIntegrate \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioIntegrate \/ Inapplicable"},{"orgOrder":0,"company":"Yale University","sponsor":"Columbia University | University of Pennsylvania | Stony Brook University | Cerevel Therapeutics | National Institute of Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PF-06412562","moa":"D1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Columbia University | University of Pennsylvania | Stony Brook University | Cerevel Therapeutics | National Institute of Mental Health","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ Columbia University | University of Pennsylvania | Stony Brook University | Cerevel Therapeutics | National Institute of Mental Health"},{"orgOrder":0,"company":"Mazra Mental Health Center","sponsor":"Ben-Gurion University of the Negev","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Oxopurin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Mazra Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mazra Mental Health Center \/ Ben-Gurion University of the Negev","highestDevelopmentStatusID":"7","companyTruncated":"Mazra Mental Health Center \/ Ben-Gurion University of the Negev"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Clinilabs | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Oxy(Gly)4-sKLH Vaccine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Clinilabs | National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"New York State Psychiatric Institute \/ Clinilabs | National Institute on Drug Abuse"},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Opioid Vaccines","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"University of Montana \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"University of Montana \/ National Institutes of Health"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.
Details :
The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.
Details :
CMND-100 (5-methoxy-2-aminoindane) is a 5-HT1A receptor modulator, small molecule drug candidate, which is being evaluated for the treatment of alcohol use disorder.
Details :
CMND-100 (5-methoxy-2-aminoindane) is a 5-HT1A receptor modulator, small molecule drug candidate, which is being evaluated for the treatment of alcohol use disorder.
Details :
CMND-100 (5-methoxy-2-aminoindane) is a 5-HT1A receptor modulator, small molecule drug candidate, which is being evaluated for the treatment of alcohol use disorder.
Details :
CMND-100 (5-methoxy-2-aminoindane) is a 5-HT inhibitor, a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of alcohol use disorder.
Details :
CMND-100 (5-methoxy-2-aminoindane) is a 5-HT inhibitor, a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of alcohol use disorder.
Reset All
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
